-
公开(公告)号：EP3725879B1
公开(公告)日：2024-07-03
申请号：EP18887944.9
申请日：2018-12-06
IPC分类号： A01K67/0275 , C12N9/02
-
公开(公告)号：EP4345164A3
公开(公告)日：2024-06-26
申请号：EP24156173.7
申请日：2011-03-31
申请人： Ablexis, LLC
发明人： GREEN, Larry , SHIZUYA, Hiroaki
IPC分类号： A01K67/0275 , C07K16/00 , C07K16/18 , C07K16/46 , C12N15/85
CPC分类号： A01K2217/05220130101 , A01K2267/0120130101 , C07K2317/2420130101 , C12N2510/0220130101 , A01K67/0275 , C07K16/00 , A01K2227/10520130101 , A01K2217/07220130101 , A01K2207/1520130101
摘要： The invention provides a mouse whose genome comprises a transgene comprising a polynucleotide sequence comprising DNA sequences corresponding to DNA sequences from a mouse immunoglobulin locus except for polynucleotide sequences encoding one or more human immunoglobulin heavy chain variable (V) polypeptide sequences, one or more human immunoglobulin heavy chain diversity (D) polypeptide sequences, and one or more human immunoglobulin heavy chain joining (J) polypeptide sequences, wherein the polynucleotide sequences encoding the one or more human heavy chain V polypeptide sequences, the one or more human heavy chain D polypeptide sequences, and the one or more human heavy chain J polypeptide sequences replace one or more mouse immunoglobulin heavy chain V coding sequences, one or more mouse immunoglobulin heavy chain D coding sequences, and one or more mouse immunoglobulin heavy chain J coding sequences, respectively.
-
公开(公告)号：EP4345163A3
公开(公告)日：2024-06-19
申请号：EP24156172.9
申请日：2011-03-31
申请人： Ablexis, LLC
发明人： GREEN, Larry , SHIZUYA, Hiroaki
IPC分类号： A01K67/0275 , C07K16/00 , C07K16/18 , C07K16/46 , C12N15/85
CPC分类号： A01K2217/05220130101 , A01K2267/0120130101 , C07K2317/2420130101 , C12N2510/0220130101 , A01K67/0275 , C07K16/00 , A01K2227/10520130101 , A01K2217/07220130101 , A01K2207/1520130101
摘要： The invention provides A mouse whose genome comprises a transgene comprising a polynucleotide sequence comprising DNA sequences corresponding to DNA sequences from a mouse immunoglobulin locus except for polynucleotide sequences encoding one or more human immunoglobulin light chain variable (V) polypeptide sequences and one or more human immunoglobulin light chain joining (J) polypeptide sequences, wherein the sequences encoding the one or more human light chain V polypeptide sequences and the one or more human light chain J polypeptide sequences replace one or more mouse immunoglobulin light chain V coding sequences and one or more mouse immunoglobulin light chain J coding sequences, respectively.
-
公开(公告)号：EP3977848B1
公开(公告)日：2024-09-25
申请号：EP20382869.4
申请日：2020-09-30
IPC分类号： A01K67/0275 , A01K67/0276 , C07K14/47 , G01N33/50
-
公开(公告)号：EP3766980B1
公开(公告)日：2024-08-07
申请号：EP19767483.1
申请日：2019-03-15
IPC分类号： A01K67/0275 , C12N5/10 , C12N15/85 , C12P21/02 , C07K16/00
-
公开(公告)号：EP3480299B1
公开(公告)日：2024-10-16
申请号：EP17819817.2
申请日：2017-06-08
-
公开(公告)号：EP3480298B1
公开(公告)日：2024-09-25
申请号：EP17819816.4
申请日：2017-06-08
IPC分类号： A01K67/0275 , A01K67/027 , A61K35/22 , A61L27/36 , A61L27/38 , A61P13/12 , C12N15/09 , C12N5/071
CPC分类号： A01K67/027 , A61L27/36 , A61L27/38 , A61K35/22 , C12N15/09 , A61P13/12 , A01K2267/02520130101 , A01K2227/10520130101 , A01K67/0275 , C12N5/0686 , A01K2217/20620130101 , A01K2217/3020130101
-
8.发明公开
公开(公告)号：EP4335927A3
公开(公告)日：2024-06-19
申请号：EP23212677.1
申请日：2016-06-16
IPC分类号： A01K67/027 , C07K14/47 , G01N33/15 , C12N15/90 , A01K67/0275 , A01K67/0271
CPC分类号： C07K14/472 , C12N15/907 , A01K2217/0720130101 , A01K2227/10520130101 , A01K2267/038720130101 , A01K67/027 , A01K67/0271 , A01K2207/1220130101 , A01K2207/1520130101 , A01K67/0275
摘要： The present invention relates generally to genetically modified non-human animals and immunodeficient non-human animals characterized by restored complement-dependent cytotoxicity, as well as methods and compositions for assessment of therapeutic antibodies in the genetically modified immunodeficient non-human animals. In specific aspects, the present invention relates to immunodeficient non-obese diabetic (NOD), A/J, A/He, AKR, DBA/2, NZB/B1N, B10.D2/oSn and other mouse strains genetically modified to restore complement-dependent cytotoxicity which is lacking in the unmodified immunodeficient mice. In further specific aspects, the present invention relates to NOD.Cg-Prkdcscid IL2rgtmlWjl/SzJ (NSG), NOD.Cg-Rag1tm1Mom IlrgtmlWjll/SzJ (NRG) and NOD.Cg-Prkdcscid Ilrgtm1Sug/JicTac (NOG) mice genetically modified to restore complement-dependent cytotoxicity which is lacking in unmodified NSG, NRG and NOG mice. Methods for assessment of therapeutic antibodies in the genetically modified immunodeficient mice characterized by an intact complement system, such as NSG, NRG and NOG mice characterized by an intact complement system are provided according to specific aspects of the present invention.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.008 秒)
